PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs: approval selpercatinib for solid tumor with RET fusion, gumarontinib for non-small cell lung cancer with MET gene exon 14 skipping mutation, momelotinib for myelofibrosis, bexarotene for adult T-cell leukemia/lymphoma, valemetostat for peripheral T-cell lymphoma, and pirtobrutinib for mantle cell lymphoma in Japan.
作者信息
Matsumura Noriomi, Mandai Masaki
机构信息
Kindai University, Faculty of Medicine, Osaka, Japan.
Editorial Committee, Japan Society of Clinical Oncology, Tokyo, Japan.
出版信息
Int J Clin Oncol. 2024 Sep;29(9):1207-1208. doi: 10.1007/s10147-024-02579-z.
PMID:39007945
Abstract
摘要
Zotero 插件